Pathogenesis and clinical translation of intrahepatic cholangiocarcinoma in the era of precision medicine

Wenhua YOU; Yuan LIANG; Ling LYU

doi:10.3969/j.issn.1001-5256.2021.04.045

Volume 37 Issue 4

Apr. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(4): 935-938

PDF( 1903 KB)

Pathogenesis and clinical translation of intrahepatic cholangiocarcinoma in the era of precision medicine

DOI: 10.3969/j.issn.1001-5256.2021.04.045

Wenhua YOU^{1, 2},
Yuan LIANG^{1, 2},
Ling LYU^{2
,
,}

1.
School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing 211166, China
2.
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Received Date: 2020-09-16
Accepted Date: 2020-10-16
Published Date: 2021-04-20

Abstract

Abstract

Intrahepatic cholangiocarcinoma (ICC) is an important liver malignancy next only to hepatocellular carcinoma, accounting for 15%-20% of primary liver cancer. In recent years, the incidence rate of ICC tends to increase globally; however, due to its insidious onset, high degree of malignancy, and strong invasive ability, most patients are in the advanced stage when attending the hospital and thus miss the most appropriate timing for surgery. With the continuous development of next-generation sequencing, the treatment of ICC gradually develops towards the direction of individualization and precision. This article introduces the basic research advances in the pathogenesis, molecular typing, and early diagnosis of ICC and reviews the clinical translational research of ICC in recent years, so as to provide new ideas for the treatment and clinical research of ICC.
- Cholangiocarcinoma,
- Tumor Microenvironment,
- Diagnosis,
- Therapeutics

FullText(HTML)

References(41)

References

[1]	KHAN SA, THOMAS HC, DAVIDSON BR, et al. Cholangiocarcinoma[J]. Lancet, 2005, 366(9493): 1303-1314. DOI: 10.1016/S0140-6736(05)67530-7
[2]	BRIDGEWATER J, GALLE PR, KHAN SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2014, 60(6): 1268-1289. DOI: 10.1016/j.jhep.2014.01.021
[3]	SAHA SK, ZHU AX, FUCHS CS, et al. Forty-year trends in cholangiocarcinoma incidence in the U.S. : Intrahepatic disease on the rise[J]. Oncologist, 2016, 21(5): 594-599. DOI: 10.1634/theoncologist.2015-0446
[4]	LIU ZH, CHEN Z, MA LL, et al. Factors influencing the prognosis of patients with intrahepatic cholangiocarcinoma[J]. Acta Gastroenterol Belg, 2012, 75(2): 215-218. http://www.ncbi.nlm.nih.gov/pubmed/21431970
[5]	YOH T, HATANO E, SEO S, et al. Long-term survival of recurrent intrahepatic cholangiocarcinoma: The impact and selection of repeat surgery[J]. World J Surg, 2018, 42(6): 1848-1856. DOI: 10.1007/s00268-017-4387-7
[6]	HWANG S, LEE YJ, SONG GW, et al. Prognostic impact of tumor growth type on 7th AJCC staging system for intrahepatic cholangiocarcinoma: A single-center experience of 659 cases[J]. J Gastrointest Surg, 2015, 19(7): 1291-1304. DOI: 10.1007/s11605-015-2803-6
[7]	MOEINI A, SIA D, BARDEESY N, et al. Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma[J]. Clin Cancer Res, 2016, 22(2): 291-300. DOI: 10.1158/1078-0432.CCR-14-3296
[8]	FAN B, MALATO Y, CALVISI DF, et al. Cholangiocarcinomas can originate from hepatocytes in mice[J]. J Clin Invest, 2012, 122(8): 2911-2915. DOI: 10.1172/JCI63212
[9]	SEKIYA S, SUZUKI A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes[J]. J Clin Invest, 2012, 122(11): 3914-3918. DOI: 10.1172/JCI63065
[10]	GUEST RV, BOULTER L, KENDALL TJ, et al. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma[J]. Cancer Res, 2014, 74(4): 1005-1010. DOI: 10.1158/0008-5472.CAN-13-1911
[11]	NAKAMURA H, ARAI Y, TOTOKI Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47(9): 1003-1010. DOI: 10.1038/ng.3375
[12]	FARSHIDFAR F, ZHENG S, GINGRAS MC, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles[J]. Cell Rep, 2017, 18(11): 2780-2794. DOI: 10.1016/j.celrep.2017.02.033
[13]	WANG L, ZHU H, ZHAO Y, et al. Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience[J]. J Transl Med, 2020, 18(1): 273. DOI: 10.1186/s12967-020-02437-2
[14]	ANDERSEN JB, THORGEIRSSON SS. Genetic profiling of intrahepatic cholangiocarcinoma[J]. Curr Opin Gastroenterol, 2012, 28(3): 266-272. DOI: 10.1097/MOG.0b013e3283523c7e
[15]	MENG F, WEHBE H, HENSON R, et al. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes[J]. Oncogene, 2008, 27(3): 378-386. DOI: 10.1038/sj.onc.1210648
[16]	PLIESKATT J, RINALDI G, FENG Y, et al. A microRNA profile associated with Opisthorchis viverrini-induced cholangiocarcinoma in tissue and plasma[J]. BMC Cancer, 2015, 15: 309. DOI: 10.1186/s12885-015-1270-5
[17]	MENG F, HENSON R, LANG M. et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines[J]. Gastroenterology, 2006, 130(7): 2113-2129. DOI: 10.1053/j.gastro.2006.02.057
[18]	ZHANG M, YANG H, WAN L, et al. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma[J]. J Hepatol, 2020, 73(5): 1118-1130. DOI: 10.1016/j.jhep.2020.05.039
[19]	MCNAMARA MG, TEMPLETON AJ, MAGANTI M, et al. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer[J]. Eur J Cancer, 2014, 50(9): 1581-1589. DOI: 10.1016/j.ejca.2014.02.015
[20]	ZHOU SL, DAI Z, ZHOU ZJ, et al. CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils[J]. Carcinogenesis, 2014, 35(3): 597-605. DOI: 10.1093/carcin/bgt397
[21]	SUBIMERB C, PINLAOR S, KHUNTIKEO N, et al. Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma[J]. Mol Med Rep, 2010, 3(4): 597-605. http://www.ncbi.nlm.nih.gov/pubmed/21472285
[22]	BOULTER L, GUEST RV, KENDALL TJ, et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited[J]. J Clin Invest, 2015, 125(3): 1269-1285. DOI: 10.1172/JCI76452
[23]	VIVIER E, UGOLINI S, BLAISE D, et al. Targeting natural killer cells and natural killer T cells in cancer[J]. Nat Rev Immunol, 2012, 12(4): 239-252. DOI: 10.1038/nri3174
[24]	SEEHAWER M, HEINZMANN F, D'ARTISTA L, et al. Necroptosis microenvironment directs lineage commitment in liver cancer[J]. Nature, 2018, 562(7725): 69-75. DOI: 10.1038/s41586-018-0519-y
[25]	JOB S, RAPOUD D, DOS SANTOS A, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma[J]. Hepatology, 2020, 72(3): 965-981. DOI: 10.1002/hep.31092
[26]	CHAISAINGMONGKOL J, BUDHU A, DANG H, et al. Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma[J]. Cancer Cell, 2017, 32(1): 57-70.e3. DOI: 10.1016/j.ccell.2017.05.009
[27]	SIA D, HOSHIDA Y, VILLANUEVA A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes[J]. Gastroenterology, 2013, 144(4): 829-840. DOI: 10.1053/j.gastro.2013.01.001
[28]	XU RH, WEI W, KRAWCZYK M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater, 2017, 16(11): 1155-1161. DOI: 10.1038/nmat4997
[29]	SHEN N, ZHANG D, YIN L, et al. Bile cell-free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer[J]. Oncol Rep, 2019, 42(2): 549-560. http://www.researchgate.net/publication/333518985_Bile_cell-free_DNA_as_a_novel_and_powerful_liquid_biopsy_for_detecting_somatic_variants_in_biliary_tract_cancer
[30]	ARBELAIZ A, AZKARGORTA M, KRAWCZYK M, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma[J]. Hepatology, 2017, 66(4): 1125-1143. DOI: 10.1002/hep.29291
[31]	YANG JD, CAMPION MB, LIU MC, et al. Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma[J]. Hepatology, 2016, 63(1): 148-158. DOI: 10.1002/hep.27944
[32]	LAMARCA A, PALMER DH, WASAN HS, et al. ABC-06 \| A randomised phase Ⅲ, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy[J]. J Clin Oncol, 2019, 37(15 Suppl): 4003.
[33]	BEKAⅡ-SAAB TS, VALLE JW, CUTSEM EV, et al. FIGHT-302: First-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements[J]. Future Oncol, 2020, 16(30): 2385-2399. DOI: 10.2217/fon-2020-0429
[34]	ABOU-ALFA GK, SAHAI V, HOLLEBECQUE A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2020, 21(5): 671-684. DOI: 10.1016/S1470-2045(20)30109-1
[35]	ABOU-ALFA GK, MACARULLA T, JAVLE MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 796-807. DOI: 10.1016/S1470-2045(20)30157-1
[36]	BANG YJ, UENO M, MALKA D, et al. Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies[J]. J Clin Oncol, 2019, 37(15_Suppl): 4079. DOI: 10.1200/JCO.2019.37.15_suppl.4079
[37]	LIN J, SHI W, ZHAO S, et al. Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): Preliminary data and correlation with next-generation sequencing[J]. J Clin Oncol, 2018, 36(4 Suppl): 500. http://www.researchgate.net/publication/330096463_Lenvatinib_plus_checkpoint_inhibitors_in_patients_pts_with_advanced_intrahepatic_cholangiocarcinoma_ICC_Preliminary_data_and_correlation_with_next-generation_sequencing
[38]	CHEN WX, LI GX, HU ZN, et al. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review[J]. Medicine (Baltimore), 2019, 98(45): e17832. DOI: 10.1097/MD.0000000000017832
[39]	QIN S, CHEN Z, LIU Y, et al. A phase Ⅱ study of anti-PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer[J]. J Clin Oncol, 2019, 37(15 Suppl): 4074. http://www.researchgate.net/publication/333406920_A_phase_II_study_of_anti-PD-1_antibody_camrelizumab_plus_FOLFOX4_or_GEMOX_systemic_chemotherapy_as_first-line_therapy_for_advanced_hepatocellular_carcinoma_or_biliary_tract_cancer
[40]	OH D, LEE K, LEE D, et al. Phase Ⅱ study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ±tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC)[J]. J Clin Oncol, 2020, 38(15 Suppl): 4520. http://www.researchgate.net/publication/341632436_Phase_II_study_assessing_tolerability_efficacy_and_biomarkers_for_durvalumab_D_tremelimumab_T_and_gemcitabinecisplatin_GemCis_in_chemo-naive_advanced_biliary_tract_cancer_aBTC
[41]	SAHAI V, GRIFFITH K A, BEG M S, et al. A multicenter randomized phase Ⅱ study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01)[J]. J Clin Oncol, 2020, 38(15 Suppl): 4582.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (904) PDF downloads(97)

Pathogenesis and clinical translation of intrahepatic cholangiocarcinoma in the era of precision medicine

DOI: 10.3969/j.issn.1001-5256.2021.04.045

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Pathogenesis and clinical translation of intrahepatic cholangiocarcinoma in the era of precision medicine

DOI: 10.3969/j.issn.1001-5256.2021.04.045

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content